Technology is transforming how clinical trials are run. A panel during MedCity News’ INVEST Digital Health conference discussed the tech trends shaping the design and execution of drug studies.
Digital health's investment slowdown is so severe that the fourth quarter of 2022 marked the lowest quarterly digital health funding total in the past five years, according to new report. Q4 was also the first quarter with no new unicorn births since 2018.
At the 5th annual HLTH conference in Las Vegas, 14 healthcare executives from companies such as Babson Diagnostics to Wheel responded to questions such as what's the difference between a positive and negative user experience in telehealth? They also previewed their plans for 2023.
MedCity News interviewed CEOs of public companies, entrepreneurs, VCs and payers at the HLTH conference that concluded last week. They had a range of answers to the question. But one common theme emerged: Currently, everyone has a vise-like grip on expenditure.
A panel of healthcare data experts recently broke down some of healthcare’s most common buzzwords at HLTH. While the experts agreed that many industry professionals still struggle to grasp the true denotations of words and phrases like “interoperability” and “reimagining healthcare,” the panelists said these terms can be quite meaningful once they’re unpacked.
Hear from healthcare executives such as CVS Kidney Care President Lisa Rometty, Komodo Health CEO Dr. Arif Nathoo, and McKesson Ventures Partner Michelle Snyder on how they're thinking about digital transformation in healthcare in a series of interviews at ViVE.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Real-world data has long been touted as the solution to many challenges faced in the healthcare space – but more data doesn’t necessarily mean more answers. RWD has become the lynchpin to a more patient-centric approach to care, from drug development to therapy access and provider engagement. But until the tools and technology are in place to turn that data into actionable insights, in context, they’re nothing but numbers. Join us for a discussion on the crucial role of real world data and advanced analytics in the digital transformation of the life sciences industry.
INVEST Digital Health is set for September 20-23, and held in collaboration with Medical Alley. The healthcare conference, held in a virtual format due to Covid-19, brings together innovative investors across the healthcare spectrum, prominent industry players and the most promising digital health startups.
SDoH is just one of the topics at the MedCity INVEST Digital Health conference, a virtual event scheduled for September 20-23, in collaboration with Medical Alley.
The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This panel explores some of the diverse approaches companies are taking to improve efficiency and avert pitfalls in therapeutic development.
The clinical trial arena is changing rapidly, driven largely by the acceleration of telehealth usage and the potential provided by new data solutions. Panelists at MedCity INVEST Precision Medicine agreed that clinical trials will never be conducted in the same way again.
Register for INVEST Precision Medicine to check out the life science track of the Pitch Perfect startup contest and hear compelling panel discussions on software supporting biopharma R&D, and the supply chain challenges of scaling production and delivering personalized therapies.
The conference, set for June 9-11, will explore different aspects of precision medicine, including the software being used to support drug and therapeutic development.
With artificial intelligence and machine learning algorithms are becoming more in vogue in different aspects of healthcare, our panel discusses how can we ensure that AI is leveraged properly so that it advances the goals of health equity.
